期刊文献+

新一代四环素类药物替加环素的研究进展 被引量:15

Research Development of Tigecycline:A New Glycylcycline Antimicrobial Agent
下载PDF
导出
摘要 对于日益增多的危及生命的多药耐药菌的爆发与流行,临床上迫切需要新的抗生素,替加环素以其广谱、高效,较高的性价比,满足了人们这一需求。综述了近年来替加环素的研究进展,包括体内外的抗菌活性、抗生素后效应、药代动力学、不良反应、药物相互作用、临床研究、克服细菌耐药的机理、性价比等各个方面。替加环素是一个比较理想的药物,对大多数耐药菌都有较强的抑制力,适合于治疗复杂的具有耐药的感染。 New antimicrobial agents are urgently needed for clinical use due to the increasing prevalence and spread of multidrug-resistant bacteria that are commonly responsible for serious and life-threatening diseases. Tigecycline , an analogue of minocycline with additional properties of broad spectrum, high preformance, higher ratio of cost and effect, can satisfy the demand, the research development is review of tigecycline,included the antibacterial activity in and out of vivo, post antibiotics effect, pharmacokinetics, adverse effect, drug interaction, clinical research, overcome the mechanisms of overcome bacteria resistance, the ratio of cost and effect, etc. conclude, tigecycline is and idea drugs, have a good effect on the most of resistant bacteria, and fit for treatment of complicated and drug resistant infection.
作者 程仕虎 王睿
出处 《科学技术与工程》 2007年第16期4123-4130,共8页 Science Technology and Engineering
关键词 替加环素 抗力 敏感性 替代物 glycylcyclines resistance in vitro susceptibility new antib
  • 相关文献

参考文献50

  • 1[1]Biedenbach D J,Beach M L,Jones R N.In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant Gram-positive blood stream infection isolate sandstrains producing extended spectrumb-lactamases.Diagn Microbiol Infect Dis,2001; 40:173-177
  • 2[2]Gales A C,Jones R N.Antimicrobial activity and spectrum of the new glycylcycline,GAR -936 tested against 1,203 recent clinical bacterial isolates.Diagn Microbiol Infect Dis,2000; 36:19-36
  • 3[3]Postier R G,Green S L,Klein S R,et al.Tigecycline 200 study group.results of a multicenter,randomized,open-label efficacy and safety study of two doses of tigecycline for complicated skin and skinstructure infections in hospitalized patients.Clin Ther,2004; 26:704-714
  • 4[4]Petersen P J,Jacobus N V,Weiss W J,et al.In vitro and in vivo antibacterial activities of a novel glycylcycline,the 9-t-butylglycylamido derivative of minocycline (GAR -936).Antimicrob Agents Chemother,1999; 43:738-744
  • 5[5]Milatovic D,Schmitz F J,Verhoef J,et al.Activities of the glycylcycline tigecycline (GAR-936) against 1924 recent European clinical bacterial isolates.Antimicrob Agents Chemother,2003; 47:400-404
  • 6[6]Betriu C,Rodriguez-Avial I,Sanchez B A,et al; Spanish Group of Tigecycline.In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain.Antimicrob Agents Chemother,2002; 46:892-135
  • 7[7]Cercenado E,Cercenado S,Gomez J A,et al.In vitro activity of tigecycline (GAR-936),a novel glycylcycline,against vancomycinresistant enterococci and staphylococci with diminished susceptibility to glycopeptides (letter).Antimicrob Chemother 2003; 52:138-139
  • 8[8]Murray J,Wilson S,Klein S,et al.The clinical response to tigecycline in the treatment of complicated intra-abdominal infections in hospitalized patients,a phase 2 clinical trial.In:Programs and Abstracts of the Fortythird Interscience Conference on Antimicrobial Agents and Chemotherapy,Chicago,IL,2003:Abstract L-739,416
  • 9[9]Deshpande LM,Gales AC,Jones RN.GAR-936 susceptibility test development for streptococci,Haemophilus influenzae and Neisseria gonorrhoeae:preliminary guidelines and interpretive criteria.Int J Antimicrob Agents,2001,18:29-35
  • 10[10]Henwood C J,Gatward T,Warner M,et al.Antibiotic resistance among clinical isolates of Acinetobacter in the UK,and in vitro evaluation of tigecycline (GAR-936).Antimicrob Chemother,2002;49:479-487

同被引文献178

引证文献15

二级引证文献80

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部